MET ex14 Skipping Treatment Market

Future Market Insights

Key Insight

The MET ex14 skipping treatment market is projected to grow from USD 186.7 million in 2025 to USD 353.7 million by 2035, at a CAGR of 6.6%. Tepotinib will dominate with a 29.0% market share, while hospital will lead the application segment with a 54.0% share.

November 13, 2025

Anurag Sharma

250 Pages

Cite this Report

MET ex14 Skipping Treatment Market

https://www.futuremarketinsights.com/reports/met-ex14-skipping-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Avistone
HUTCHMED
Haihe Biopharma
Merck KGaA
Novartis

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

MET ex14 Skipping Treatment Market

Key Players

Similar Industry Reports